基线HbA1c与心血管及肾脏结局的关联:来自DECLARE-TIMI 58的分析
基于DECLARE-TIMI 58试验中17,160例2型糖尿病患者,中位随访4.2年,分析基线HbA1c与心血管及肾脏结局的关联及达格列净获益是否随基线HbA1c变化。结果显示基线HbA1c越高,心血管死亡/心衰住院、MACE及心肾结局风险越高,尤其在多危险因素人群中;达格列净的获益在各HbA1c亚组中一致,无异质性。
要点
- 基线HbA1c每升高1%,心血管死亡/心衰住院风险调整HR 1.12(95%CI 1.06-1.19)。
- 基线HbA1c每升高1%,MACE风险调整HR 1.08(95%CI 1.04-1.13)。
- 达格列净降低心血管死亡/心衰住院、心衰住院及心肾结局风险,各HbA1c亚组无显著异质性(交互P>0.05)。
核心结论
- 较高的HbA1c水平与更高的心血管和肾脏风险相关,尤其是在多危险因素人群中,但达格列净的获益在所有亚组中均可观察到,与基线HbA1c无关,包括HbA1c<7%的患者。
研究设计与样本
- DECLARE-TIMI 58试验为随机对照试验,17,160例2型糖尿病患者随机分配至达格列净或安慰剂,中位随访4.2年。
- 采用Cox回归模型分析总体人群中基线HbA1c与心血管及肾脏结局的关联,以及达格列净与安慰剂在各HbA1c亚组中的对比。
主要发现
- 总体人群中,基线HbA1c每升高1%,心血管死亡或心衰住院的风险调整HR为1.12(95%CI 1.06-1.19)。
- 基线HbA1c每升高1%,MACE(包括心血管死亡、心肌梗死和缺血性卒中)的风险调整HR为1.08(95%CI 1.04-1.13)。
- 基线HbA1c每升高1%,心肾结局的风险调整HR为1.17(95%CI 1.11-1.24)。
- 与已确诊ASCVD患者相比,多危险因素(MRF)患者中HbA1c升高与MACE和心肾结局风险增加关联更强(交互P分别为0.0064和0.0093)。
- 与安慰剂相比,达格列净降低心血管死亡/心衰住院、心衰住院及心肾结局风险,各基线HbA1c亚组间无显著异质性(交互P>0.05)。
临床怎么用
- 当前指南推荐对2型糖尿病合并确诊或高危动脉粥样硬化性心血管疾病(ASCVD)的患者处方SGLT2抑制剂,无论HbA1c水平如何。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Current guidelines recommend prescribing SGLT2 inhibitors to patients with type 2 diabetes and established or at high risk for atherosclerotic cardiovascular disease (ASCVD), irrespective of HbA1c levels. We studied the association of HbA1c with cardiovascular and renal outcomes and whether the benefit of dapagliflozin varies by baseline HbA1c. RESEARCH DESIGN AND METHODS: In the Dapagliflozin Effect on Cardiovascular Events trial (DECLARE-TIMI 58), 17,160 patients with type 2 diabetes were randomly assigned to dapagliflozin or placebo for a median follow-up of 4.2 years. Cardiovascular and renal outcomes by baseline HbA1c in the overall population and with dapagliflozin versus placebo in HbA1c subgroups were studied by Cox regression models. RESULTS: In the overall population, higher baseline HbA1c was associated with a higher risk of cardiovascular death or hospitalization for heart failure (HHF); major adverse cardiovascular events (MACE), including cardiovascular death, myocardial infarction, and ischemic stroke; and cardiorenal outcomes (adjusted hazard ratios 1.12 [95% CI 1.06-1.19], 1.08 [1.04-1.13], and 1.17 [1.11-1.24] per 1% higher level, respectively). Elevated HbA1c was associated with a greater increased risk for MACE and cardiorenal outcomes in patients with multiple risk factors (MRF) than in established ASCVD (P-interaction = 0.0064 and 0.0093, respectively). Compared with placebo, dapagliflozin decreased the risk of cardiovascular death/HHF, HHF, and cardiorenal outcomes, with no heterogeneity by baseline HbA1c (P-interaction > 0.05). CONCLUSIONS: Higher HbA1c levels were associated with greater cardiovascular and renal risk, particularly in the MRF population, yet the benefits of dapagliflozin were observed in all subgroups irrespective of baseline HbA1c, including patients with HbA1c <7%.
引用
- Cahn A, Wiviott SD, Mosenzon O, et al. Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58. Diabetes Care. 2022. PMID: 35015847. doi:10.2337/dc21-1744
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。